Alcohol

Alcohol

SCHEMBL5419944

CCO.Cc1cn2cc(C(=O)N(C)C)cc(O)c2n1

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.33
ALPL P05186 2/20 0.33
PLAA Q9Y263 2/20 0.33
ALPG P10696 2/20 0.33
ALPI P09923 1/20 0.31
TGFBR1 P36897 1/20 0.31
PDK2 Q15119 1/20 0.30
PDK4 Q16654 1/20 0.30
ERN1 O75460 1/20 0.30
TSHR P16473 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
ACSS2 Q9NR19 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411738 0.94 ALPL (0.33) GRM5ALPLPLAAALPGALPI
SCHEMBL31309554 0.78 MYC (0.41) GRM5ALPLPLAAALPGGAA
SCHEMBL31309517 0.78 GRM5 (0.51) GRM5NPSR1
Alcohol SCHEMBL4974198 0.77 CYP3A4 (0.38) PLAAALPGALPIPDK2PDK4
SCHEMBL5416684 0.73 KDM4E (0.37) TSHRGAA
SCHEMBL5036927 0.70 CYP3A4 (0.35) PDK2ERN1GAA
Alcohol SCHEMBL5567725 0.70 KDM4E (0.36) TSHRGAA
SCHEMBL31393154 0.67 TRPM8 (0.36) GRM5
SCHEMBL8376019 0.66 PIK3R1 (0.33) GRM5GAA
SCHEMBL31210532 0.66 RXFP1 (0.45) TSHRNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191334-A1 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-08-16 US disclosed
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed
EP-1735318-A2 7H-8,9-DIHYDRO-PYRANO(2,3-C)IMIDAZO(1,2A)PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2006-12-27 EP disclosed
EP-1696921-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS Altana Pharma AG (DE) 2006-09-06 EP disclosed
WO-2005090358-A2 7H-8,9-DIHYDRO-PYRANO (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed
WO-2005058325-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191334-A1 Tricyclic imidazopyridines GIPR, SLC10A2, MLNR GRM5 646/4885ALPL 2935/4885PLAA 3941/4885
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR GRM5 507/4885ALPL 4102/4885PLAA 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.